#1GE GE HealthCare GE HealthCare Investor Day | December 8, 2022#2GE HealthCare Today's Agenda Opening Remarks Vision & Strategy for Long-Term Value Creation Imaging Ultrasound Patient Care Solutions Pharmaceutical Diagnostics Commercial Strategy and Execution Q&A BREAK Financial Strategy Larry Culp, Chairman of the Board Peter Arduini, CEO Jan Makela, Imaging CEO Roland Rott, Ultrasound CEO Thomas Westrick, Patient Care Solutions CEO Kevin O'Neill, Pharmaceutical Diagnostics CEO Catherine Estrampes, U.S. & Canada, CEO Segment Leaders and Peter Arduini Q&A Closing Remarks Helmut Zodl, CFO Peter Arduini and Helmut Zodl Peter Arduini © 2022, General Electric Company. Proprietary information. All rights reserved. 2#3Disclaimer EGE HealthCare This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would," "could," "plan," "believe," "anticipate,” “intend,” “estimate,” “potential," "position," "forecast,” “target," "outlook," and similar expressions. These forward-looking statements may include, but are not limited to, statements about the Company's expected financial performance and financial condition, including revenue growth, profit, cash flows, and earnings per share and the Company's 2022 outlook; taxes; the impacts of macroeconomic and market conditions and volatility on the Company's business operations, financial results and financial position and on the global supply chain and world economy; the Company's strategy, innovation and investments; the Company's cost structure; the Company's funding and liquidity; and the impacts of the COVID-19 pandemic. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company's control. Factors that could cause our actual results to differ materially from those described in the Company's forward-looking statements include, but are not limited to, operating in highly competitive markets; the actions or inactions of third parties with whom the Company partners and the various collaboration, licensing, and other partnerships and alliances the Company has with third parties; demand for the Company's products, services, or solutions and factors that affect that demand; management of the Company's supply chain and the Company's ability to cost-effectively secure the materials it needs to operate its business; disruptions in the Company's operations; the global COVID-19 pandemic and its effects on the Company's business; maintenance and protection of the Company's intellectual property rights; the impact of potential information technology, cybersecurity or data security breaches; compliance with the various legal, regulatory, tax, and other laws to which the Company is subject and related changes, claims, or actions; environmental, social, and governance matters; the Company's ability to successfully complete strategic transactions; the Company's ability to operate effectively as an independent, publicly-traded company and achieve the benefits the Company expects from its spin-off from General Electric Company; and the incurrence of substantial indebtedness in connection with the spin-off and any related effect on the Company's business. Please also see the "Risk Factors" section of the Company's Form 10 filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company's actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation. Use of Non-GAAP Financial Measures In this presentation, we use some information derived from consolidated financial data but not presented in accordance with U.S. generally accepted accounting principles ("GAAP"). These are considered "non-GAAP financial measures" under SEC rules. These non-GAAP financial measures supplement our disclosures and should not be considered an alternative to the comparable GAAP measure. Please see the end of this presentation for GAAP to non-GAAP reconciliations including comparable GAAP measures, and please see our Form 10 for more information on the reasons we use these non-GAAP financial measures. Financial Comparisons References to results increasing, decreasing, or remaining flat are in comparison to the same period in the prior fiscal year. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis. Product Status Not all products or features are available in all markets. The information presented here may involve technologies and concepts in development that are not products and may never become products. For Technology in Development, the technologies or concepts are not being offered for sale, and are not cleared or approved by the U.S. FDA or any other global regulator for commercial availability © 2022, General Electric Company. Proprietary information. All rights reserved. 3#4(GE HealthCare Opening Remarks Larry Culp Chairman of the Board#5Catalyst Moment +11,00.00 (GE HealthCare Greater focus and accountability to serve patients and customers Team alignment ... dedicated talent, Board of Directors, and investors Enhanced capital allocation and strategic flexibility © 2022, General Electric Company. Proprietary information. All rights reserved. 5 LO#6Experienced and Diverse Board of Directors (GE HealthCare LARRY CULP Chairman & CEO, GE; CEO, GE Aerospace PETER ARDUINI CEO, GE HealthCare DR. RODNEY F. HOCHMAN President and CEO of Providence St. Joseph Health LLOYD W. HOWELL, JR. CFO and Treasurer of Booz Allen Hamilton Holding Company DR. RISA LAVIZZO- MOUREY Former CEO of the Robert Wood Johnson Foundation CATHERINE LESJAK Former CFO of HP ANNE T. MADDEN SVP and General Counsel of Honeywell International DR. TOMISLAV MIHALJEVIC CEO and President of Cleveland Clinic WILLIAM J. STROMBERG Non-executive Chair of the Board of T. Rowe Price Group PHOEBE L. YANG Former GM at Amazon Web Services, Healthcare © 2022, General Electric Company. Proprietary information. All rights reserved. 6#7Highly Qualified Leadership Team Driving Growth (GE HealthCare Strong track record of growth, innovation and operational execution ✔ Extensive industry and customer knowledge ✓ Deep experience in healthcare and M&A Focused Company Driving Precision Care, Well-positioned To Create Significant Value © 2022, General Electric Company. Proprietary information. All rights reserved. 7#8(GE HealthCare Vision and Strategy for Long-Term Value Creation Peter Arduini CEO#9GE HealthCare Create a world where healthcare has no limits 37.0#10Accomplished Leadership Team with Strong Track Record (GE HealthCare PETER ARDUINI JAN MAKELA ROLAND ROTT TOM WESTRICK KEVIN O'NEILL CATHERINE ESTRAMPES ROB WALTON YIHAO ZHANG ELIE CHAILLOT CEO CEO, Imaging CEO, Ultrasound CEO, PCS CEO, PDX CEO, USCAN CEO, EMEA CEO, China CEO, Intercon'tl Speaker HELMUT ZODL VP/CFO BETTY LARSON FRANK JIMENEZ Chief People Officer VP/GC MIKE DONOHOE VP Lean, Chief Transformation Officer LAILA GURNEY Chief Quality & Regulatory Officer KEN STACHERSKI Chief Integrated Supply Chain & Services Officer ABBY EPANE-OSUALA Chief Diversity, Equity, & Inclusion Officer © 2022, General Electric Company. Proprietary information. All rights reserved. 10 10#11Clear Path to Accelerate Long-Term Shareholder Value Global Leader in Attractive, Growing Market Executing on Precision Care Strategy *Non-GAAP Financial Measure. Medium-term targets. Increased Focus and Agility Driving Growth St Mid-single digit Organic Revenue Growth* High-teens to 20% Adj. EBIT Margin* Strong Free Cash Flow* Generation 980 Disciplined Capital Allocation © 2022, General Electric Company. Proprietary information. All rights reserved. 11#12Clear Path to Accelerate Long-Term Shareholder Value Global Leader in Attractive, Growing Market Executing on Precision Care Strategy *Non-GAAP Financial Measure. Medium-term targets. Increased Focus and Agility Driving Growth G Mid-single digit Organic Revenue Growth* High-teens to 20% Adj. EBIT Margin* Strong Free Cash Flow Generation 998 St 990 Disciplined Capital Allocation © 2022, General Electric Company. Proprietary information. All rights reserved. 12#13Leader in Attractive, Growing Global Market Global Leader in Attractive, Growing Market $84 billion >~$100 billion Total Addressable Market in 2021 Estimated by 2025 Global trends: ✓ Aging population Demand for insights & productivity Alternative sites of care Attractive Growth Markets with Potential to Increase TAM With Adjacencies And White Spaces-a) (a Source: GE HealthCare estimates, drawn from COCIR, NEMA, IPSOS, Signify, BCG, Bain. Includes radtiotherapeutics, endoscopes, interventional devices and virtual hospital. © 2022, General Electric Company. Proprietary information. All rights reserved. 13#14Leadership Positions in All Four Business Segments Global Leader in Attractive, Growing Market W Imaging Ultrasound Patient Care Solutions (PCS) Pharmaceutical Diagnostics (PDX) Industry Size '21-a) $44B $12B $18B $10B Industry CAGR '22-'25-a) 4-6% 4-7% 3-6% 4-5% Attractive End Markets Support Strong Growth Opportunities Across Segments (a - Based on GE HealthCare estimates and Signify Research for digital solutions © 2022, General Electric Company. Proprietary information. All rights reserved. 14 14#15GE HealthCare's Extensive Reach at a Glance Patients 1B+ served annually mall Global Leader in Attractive, Growing Market Annual R&D & product ~$1B investment spend Revenue $18B (-50% $18B recurring-a)) 4M+ base Installed 828 18.5K facing Customer- employees Notes: Figures as of 2021 unless otherwise noted (a - Comprised of services, single-use and consumable products, digital solutions, and value-added offerings, such as education, training, and consulting (b Source: As of October 2022: https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and- machine-learning-aiml-enabled-medical-devices Al-enabled device 42 authorizations in U.S., top of recent FDA list-b) © 2022, General Electric Company. Proprietary information. All rights reserved. 15 15#16At the Forefront of Care Delivery Across the Patient Journey Global Leader in Attractive, Growing Market Prevention/Screening Diagnosis Treatment Monitoring Hospitals | Ambulatory Surgery Centers | Outpatient Clinics | Physicians' Offices | Home Improving Patient Outcomes & Customer Productivity With Integrated Products & Installed Base Upgradeability © 2022, General Electric Company. Proprietary information. All rights reserved. 16#17Clear Path to Accelerate Long-Term Shareholder Value Global Leader in Attractive, Growing Market Executing on Precision Care Strategy Increased Focus and Agility Driving Growth G Mid-single digit Organic Revenue Growth* High-teens to 20% Adj. EBIT Margin* Strong Free Cash Flow Generation 990 St 998 Disciplined Capital Allocation *Non-GAAP Financial Measure. Medium-term targets. © 2022, General Electric Company. Proprietary information. All rights reserved. 17 14#18Precision Care leverages a patient's unique data via multi-modal sources to determine the most appropriate treatment and deliver the best possible outcome Multi-modal Data Bridging Data and Technology to Deliver Insights Images Pathology Genomics Vitals/ Labs Platform & A Digital Patient Precision Diagnostics Precision Therapy Precision Monitoring © 2022, General Electric Company. Proprietary information. All rights reserved. 18#19Uniquely Positioned to Enable Precision Care Edison™M Digital Health Platform Enterprise Department Device Executing on Precision Care Strategy Delivering Precision Care Driving productivity and recurring revenue Sole Global Med Tech Player With Equipment + Digital + Imaging Agents © 2022, General Electric Company. Proprietary information. All rights reserved. 19 19#20Our Approach to Delivering Precision Care D 3 as digital platform Oncology Edison™ digital orchestrator Multivendor ecosystem Neurology 006 EC Al as enabler ...all devices, platform Cardiology Executing on Precision Care Strategy Smart Devices Disease States > Digital Platform Deliver Precision Care © 2022, General Electric Company. Proprietary information. All rights reserved. 20 20#21New Product Introductions Driving Growth Introduced ~40 New Products at RSNA 2022 Indicates Al integration Revolution Apex CT Motion Injector AIR Recon DL 3D SIGNA * AIRTM Recon DL SIGNATM (1.5 and 3T) DO Omni Legend (PET/CT) 651 13. Portrait Mobile-a) Executing on Precision Care Strategy Voluson Expert 22 OEC 3D B End-tidal Control Software-a) Vscan Air Vivid Cardiology Imaging Ultrasound Business Segments Patient Care Solutions (PCS) Pharmaceutical >35% Of Equipment Orders From NPIs In 2021-b) with continued strong growth in 2022 (a - Portrait Mobile CE marked and 510K pending in US. End-tidal-Control CE marked and FDA approved. (b-Defined as percentage of product orders received in 2021 in Imaging, Ultrasound and PCS segments for products introduced in the last 12 months. © 2022, General Electric Company. Proprietary information. All rights reserved. 21 24#22Care Pathway Strategy Enables Precision Care Al-powered CDS Suite MAC 2000 Cardiology Example CARESCAPE™ RPM Edison TM-a) MONITORING EARLY DETECTION EMERGENCY DIAGNOSIS MyOSPECT Myoview ← Executing on Precision Care Strategy Vivid™M Allia™ IGS INTERVENTION TM PLANNING EDISON DIGITAL HEALTH PLATFORM We Play Across the Care Continuum Revolution TM Apex (a- Technology in Development - not a commercial product Imaging Ultrasound Patient Care Solutions (PCS) ☐ Pharmaceutical Diagnostics (PDX) Indicates Al integration © 2022, General Electric Company. Proprietary information. All rights reserved. 22 22#23Creating an Open Health Care Ecosystem with Integrated Network Effect GEHC Imaging Fabric AI/ML Engine Third-Party Vendor & Data Integration GOO Edison TM Digital Health Platform Development Platform Open Digital Platform to Drive Better Insights and Predictive Capabilities O Connected Care Pathways Leading Devices Executing on Precision Care Strategy © 2022, General Electric Company. Proprietary information. All rights reserved. 23 23#24Higher Commercial and R&D Spend to Drive Growth Executing on Precision Care Strategy Prioritizing Fastest-Growing Areas Est. CAGR '22-'25 Premium CT / PCCT -10%-b) $1B + 2022E R&D Cardio 3-D Image-guided Therapies -15% Driving Organic Handheld Ultrasound -20% Oncology MI / Theranostics. 20%+ 35%+ NPI vitality-a) Revenue Growth* & Adjusted EBIT* MR Platforming ~5-7% Al Solutions and Edison™ Platform 25%+-c) Growing, Focused R&D Driving Innovation Releases Every 12-18 Months-d) * Non-GAAP Financial Measure (a - Defined as percentage of product orders received in 2021 in Imaging, Ultrasound and PCS segments for products introduced in the last 12 months. (b - Premium CT / Photon-Counting CT CAGR pertains to '18-'30. (c-Refers to GEHC Edison™ platform and apps revenue growth rate. All other metrics refer to end market growth rates. (d-For most product lines. © 2022, General Electric Company. Proprietary information. All rights reserved. 24 24#25COLLABORATIONS External Investments to Enhance Precision Care Strategy ACQUISITIONS ■■Prismatic sensors Photon-Counting Tech bk medical Surgical Visualization ZIONEXA CDx Imaging for Oncology Goal to make treatment faster and more precise RaySearch Laboratories Radiation Oncology Expanding into adjacencies SOPHIA GENETICS™ Precision Oncology Executing on Precision Care Strategy Oncology and Neurology Capitalizing on emerging trends Adding new capabilities for customers and patients AliveCor® Pulsenmore Alternative Care Settings Pursuing Inorganic Investments to Complement our Leading Portfolio © 2022, General Electric Company. Proprietary information. All rights reserved. 25#26Clear Path to Accelerate Long-Term Shareholder Value Global Leader in Attractive, Growing Market Executing on Precision Care Strategy *Non-GAAP Financial Measure. Medium-term targets. Increased Focus and Agility Driving Growth G Mid-single digit Organic Revenue Growth* High-teens to 20% Adj. EBIT margin* Strong Free Cash Flow Generation 998 St 990 Disciplined Capital Allocation © 2022, General Electric Company. Proprietary information. All rights reserved. 26#27Unique Culture Supports our Priorities for Growth Building Our Winning Culture Serve Our People, ROD Patients, & Customers Lead with Lean Empower Entrepreneurial Spirit Positioning our culture to enable success for our customers, patients and stakeholders Deliver The Future of Healthcare Increased Focus and Agility இ) Win Together with Inclusive Teams © 2022, General Electric Company. Proprietary information. All rights reserved. 27 27#28Optimizing our Operating Model as a Standalone Company Four Focused & Integrated Segments: Increased Focus and Agility Imaging 『 Ultrasound w Patient Care Solutions (PCS) Pharmaceutical Diagnostics (PDX) Enterprise Account Management, Service Delivery Global Digital Platform Simplified, Customer-centric Structure Increases Our Speed & Agility © 2022, General Electric Company. Proprietary information. All rights reserved. 28#29Committed to Enhancing Our ESG Strategy Five Focus Areas 1 Access to healthcare Environment • Increased Focus and Agility Goal to reduce emissions by 50% by 2030-a) and Climate • Net zero by 2050 2 Climate impact & resilience 3 Circular economy & environmental design 4 Inclusion & diversity 5 Cybersecurity & patient data Social Capital . • 31% of leadership female-b) 27% ethnically diverse-c) New Chief DE&I Officer Governance and Leadership • Enterprise Stewardship Program Completed materiality assessment Prioritizing ESG to Support Long-Term Value Creation (a Refers to Scope 1 and 2 absolute emissions versus a 2019 baseline. (b - Leadership encompasses the top 1.5% of all active employees. (c - Data representative of GE's U.S. workforce as of December 31, 2021, extracted in January 2022. © 2022, General Electric Company. Proprietary information. All rights reserved. 29 29#30Clear Path to Accelerate Long-Term Shareholder Value Global Leader in Attractive, Growing Market Executing on Precision Care Strategy Increased Focus and Agility Driving Growth St G Mid-single digit Organic Revenue Growth* High-teens to 20% Adj. EBIT Margin* Strong Free Cash Flow Generation 990 *Non-GAAP Financial Measure. Medium-term targets. © 2022, General Electric Company. Proprietary information. All rights reserved. Disciplined Capital Allocation 30 30#31Executing on Clear Growth and Margin Drivers Growth Drivers . Enhanced commercial execution and capabilities • NPIs and commercial investments Digital platform / Al and SaaS solutions Margin Drivers (GE HealthCare Higher-margin products from innovation Strategic pricing and mix, including software • Lean-driven operating model and optimization Imaging • Higher-margin NPIs • Platforming initiatives • Digital / Al driving growth Margin Priority Ultrasound PCS NPIs driving innovation • Expand into adjacencies Commercial execution • Lifecycle management • Broaden digital ecosystem • New monitoring platforms Revenue Priority Margin Priority PDX • Capacity expansion • Pricing optimization • New products Revenue Priority Clear Strategy To Drive Top- And Bottom-line Growth With Focused Strategy © 2022, General Electric Company. Proprietary information. All rights reserved. 31#32Long-Term Value Creation Framework (GE HealthCare Driving Growth MSD Organic Revenue Growth* + Adj EBIT Margin Expansion High-teens to 20%* Strong FCF* Generation Disciplined Capital Allocation Strong financial position Investment in Organic growth Investment in M&A Shareholder Value Creation *Non-GAAP Financial Measure. Medium-term targets. © 2022, General Electric Company. Proprietary information. All rights reserved. 32 32#33(GE HealthCare Imaging Jan Makela Imaging CEO#34Key Takeaways Well-positioned to capitalize on future growth with robust NPI pipeline in growth industries Recurring revenue, underpinned by services: ~50% of total GE HealthCare revenue (GE HealthCare Large, global installed base with growing fleet enterprise solutions, data integration and digital sales ✓ Expanding margins through NPIs, digitization, commercial & supply chain operations-a) (a - Expanding margins is on forward looking basis © 2022, General Electric Company. Proprietary information. All rights reserved. 34#35Imaging at a Glance $44B-a) Global End Markets Estimated CAGR of 4-6%-b) (a - Estimated for the year 2021 (b Estimated for the period 2022-2025 (c For the year 2021 (d Includes all of GE HealthCare SIGNA $9,433M-c Revenue -c) 13.1%*°) Segment EBIT Margin Leadership positions in nearly all addressable markets One of largest global installed bases of 400K medical imaging devices 8,500 field service engineers-d) (GE HealthCare 200+ Software applications © 2022, General Electric Company. Proprietary information. All rights reserved. 55 35#36Attractive End Market Trends Driving Growth Estimated End Markets (GE HealthCare New Procedures and Growing Healthcare Demand Driving Imaging Markets $44B end markets: 4-6% CAGR-a) $44B $53B-b) 2021A (a Estimated from 2022-2025 (b - Represents the midpoint of the range + Increasing penetration of imaging technologies in diagnosis Growth in broad-based population screening programs Tech/Al expanding indications for high-end diagnostic exams New therapeutic procedures require precision imaging guidance 2025E © 2022, General Electric Company. Proprietary information. All rights reserved. 36#37Industry-Leading Imaging Solutions Industry-a) Growth-b) (GE HealthCare FINANCIAL SERVICES Bone & Metabolic Health CARE PATHWAYS X-Ray CT MI & CT -$8B ~3-5% Ultrasound EDUCATION & TRAINING Image-Guided .Systems MR -$6B -5-7% ENTERPRISE SOLUTIONS IMAGING SOLUTIONS BETTER HEALTH FOR ALL X-Ray & Women's Health ~$4B -1-3% Surgical Imaging Mammography DIGITAL SOLUTIONS MRI Image-Guided Therapies ~$4B ~4-6% Molecular Imaging SERVICE & LIFECYCLE DATA INTEGRATION (b (a - For the year 2021. Total Industry size shown here excludes service capabilities and digital solutions. Estimated for the period 2022-2025 © 2022, General Electric Company. Proprietary information. All rights reserved. 37 37#38Redefining What is Possible with CT Trends Increasing CT Demand Population-based screening programs • Low-dose Lung & Colorectal cancer screening • Long Covid screening • Favorable reimbursement Trends in private insurance such as Cardiac (CCTA) with procedure volumes growing 5%-a) Artificial Intelligence adoption • Optimizing workflows: image reconstruction, patient positioning and setup (a Estimated CAGR for the period 2019-2025 - (b Technology in development not a commercial product (GE HealthCare Helping Our Healthcare Providers S Broad CT portfolio • • From industry-leading cardiac CT to high- throughput value models Improving accessibility Subscription payment models & modular design Delivers CT scanners which keep getting better • Next-generation CT Advancing progress in Deep Silicon PCCT to quantity tissue parameters & characterize disease-b) © 2022, General Electric Company. Proprietary information. All rights reserved. 38#39MR: Making the Complex Simple and Accessible to All 1743 Trends Increasing MR Demand • Radiomics (quantitative MRI) & AI Fueling research in neuroscience & oncology (GE HealthCare Upgradeability, Accessibility, Quality, Speed Fast images & better quality • AIR™ Recon DL, using Deep-Learning to remove image noise in raw data ~5M patients scanned SCIENCE BEST - OF WHAT'S вел 2022- MR delivers superior tissue specificity Capital efficiency • Early diagnosis: stroke, heart disease & cancer • Field upgradeable across platforms 0 • World's first 60 cm-to-70 cm fleet upgrade Ideal for treatment monitoring & screening Non-ionizing radiation • • Optimizing cost and scan times Faster & easier for scanning • AIR™ Coil (recognized by AuntMinnie.com, Best New Radiology Device 2019) • Improving patient experience with Al workflow © 2022, General Electric Company. Proprietary information. All rights reserved. 39#40Surgical Imaging Leadership Surgical Shift Translating to Growth REVITEVAL KAPTIONS DED SYSTEM STANDRY PRESSANY REY (GE HealthCare Precision And Efficiency Of OEC 3D Active aging population Leading to growth in orthopedic procedures (hip, knee & shoulder) OEC 3D & 3D Volume Viewer Dramatic expansion of procedure types • Growth beyond hospitals at lower-cost ambulatory surgical centers & office-based labs Surgical eco-system of imaging, procedure-navigation and robotics Expected to grow by 80%+ by 2025 Saves OR time • True 2D & 3D capable; one product for many procedures Seamless integration with existing OR workflows • Planning & confirmation directly in the OR Critical part of the full solution in Spine • Flexible to interface with 6 Nav/Robotic 3rd parties © 2022, General Electric Company. Proprietary information. All rights reserved. 40 40#41Unique Portfolio Across Molecular Medicine Increased Activity in Nuclear Medicine (NM) Cancer: #2 cause of death globally (GE HealthCare The Future of Molecular Imaging (MI) is Personal Total MI for Theranostics - GE's comprehensive & industry-leading solution 62%-a) surge in cancer incidence TracerCenter FASTlab 2 Omni Platform StarGuide Q.Thera Al-c) in the next two decades Discovery: Cyclotron, radiochemistry to drive production of new tracers. 32%-b) annual growth in Radiotherapeutics from 2020 to 2031 in NM markets with approvals of new drugs. Diagnosis: High-resolution digital PET/CT for staging and re-staging tumors Precision care leading to an expansion of clinical guidelines Across oncology, neurology and cardiology (a Source: https://www.cancer.org/research/cancer-facts-statistics/global.html (b - Projected (c 510(k) pending Treatment: Powerful digital SPECT/CT with advanced Al-powered clinical apps © 2022, General Electric Company. Proprietary information. All rights reserved. 41#42Precision Care in the Oncology Care Pathway with D3 Disease State: Prostate Cancer Patient Journey Symptoms/ Screening Diagnosis Staging Treatment Planning EGE HealthCare Therapy/ Monitoring Follow Up SignaTM Artist MR LOGIQ™ Ultrasound Devices SignaTM Architect MR Omni Legend PET/CT Revolution TM CT LOGIQ™ E10 Discovery TM RT CT MR Radiation Oncology Suite 0111 1011 0010 Digital/Data Signa TM PET/MR StarGuideTM SPECT/CT OEC® Elite CFD Theranostics Solutions & Services, Q.Thera-a) Al Dosimetry & Quantitation AW PROVIEW Edison TM Datalogue Centricity Universal Viewer™ LOGIQ™M E10 Omni Legend PET/CT Signa TM PET/MR + Quantworks Roadmap Radiomics/Predictive Analytics Integrated Care with EMR, Genomics, Pathology Precision Radiotherapy Remote Patient (MR, CT, PET) Monitoring Well-Positioned to Serve Prostate Cancer Care Pathways (a 510(k) pending © 2022, General Electric Company. Proprietary information. All rights reserved. 42 42#43Unmatched Customer Experience Through Services The Predictive Customer Experience Comprehensive World-class Service Offering-a) ~50% Total 2021 Recurring Revenue ~35% Digital Service Fix +4.5 Days Per Year of Increased Uptime-b) Award-Winning Service Ability for Customers to Reach GEHC 24x7 LEAN Parts Planning imv Part of Science and Medicine Group CT SERVICETRAK 2020 2021 imv Part of Science an ce and Medicine Group INTERVENTIONAL X-RAY SERVICETRAK" 2020 2021 imv Part of Science and Medicine Group PET SERVICETRAK 2020 2021 Lifecycle Management & System Upgradeable Strategy 2021 BEST SERVICE WINNER 2021 BEST CUSTOMER SATISFACTION WINNER: GE Healthcare GE Healthcare (a Statistics for all GE HealthCare (b Statistic for Imaging 2021 BEST SERVICE WINNER: GE Healthcare (GE HealthCare Multivendor Repair Capabilities Intelligent Remote Connectivity Efficient Commercial Upgrades & Replacements © 2022, General Electric Company. Proprietary information. All rights reserved. 43 43#44Imaging Historical Financial Summary Revenue Service $9.1B $9.4B Revenue $9.0B $7.0B $7.3B (GE HealthCare Key Drivers Customer Insights Driving Innovation Edison-enabled Al & Connectivity 2019A 2020A 2021A 2021 Q3 YTD 2022 Q3 YTD Segment EBIT Margin ✓ Large Installed Base with Upgrades & Service 13.2% 13.1% 13.2% 10.3% 10.7% ✓ YTD Margin Compression As Pricing Flows Through 2019A 2020A 2021A 2021 Q3 YTD 2022 Q3 YTD © 2022, General Electric Company. Proprietary information. All rights reserved. 44 44#45Strong Visibility to EBIT Margin Expansion (GE HealthCare -10-13% High-teens Recent Historical Segment EBIT Margin Range NP Is Commercial Execution Supply Chain, VCP & Platforming Enterprise Fleet Solutions & Digital Medium-term Target Note: Illustrative graph, not to scale © 2022, General Electric Company. Proprietary information. All rights reserved. 45 45#46Our Growth Strategies to Drive Long-Term Success (GE HealthCare 3 24 O 4 1 9 13 7 1 3 9 A 9 4 1 T x 9 Broaden Portfolio Leadership Across Care Pathways Deliver Industry-Leading Service Capabilities Expand Digital / Al Capabilities with Edison™ Focus On Execution 1 © 2022, General Electric Company. Proprietary information. All rights reserved. 46 46#47(GE HealthCare Ultrasound Roland Rott Ultrasound CEO#48Key Takeaways ✓ GEHC defining the category for over 25 years (GE HealthCare Mid-single digit growing end markets with recent expansion into high-single digit adjacencies Care pathways, Al & digital innovation spearhead future growth Strong margin profile through scale/value creation © 2022, General Electric Company. Proprietary information. All rights reserved. 48 48#49Ultrasound at a Glance Leadership position in nearly all addressable markets $12B-a) Global End Markets Industry CAGR of ~4-7%) Large global installed base of ~400K devices (GE HealthCare $3,172M-a) Revenue 27.9%-a) Segment EBIT Margin 75K+ customers in on-line customer communities >600M Ultrasound exams performed annually Source: GE HealthCare Estimates (a For the year 2021 = product and service (b - Estimated for the period 2022-2025 © 2022, General Electric Company. Proprietary information. All rights reserved. 49 49#50Mid-Single Digit Industry with High-Growth Adjacencies Estimated End Markets-a) $12B end markets: ~4-7% CAGR-b) Strong Demand for Real-Time Radiation-Free Cost-Effective Imaging $15B-C) $12B 2021A Source: GE HealthCare Estimates 2025E (a Including Digital Solutions of $1B and Service Capabilities of $4B (b From 2022- 2025 (c Represents the mid-point of the range T м GE HealthCare Compelling diagnostic capabilities and large installed base Accelerating industry expansion and adoption of therapy guidance, screening & Point-of-Care Strong growth in digital solutions and handheld industries Broad wireless, wearables & homecare acceptance © 2022, General Electric Company. Proprietary information. All rights reserved. 50 50#51Industry-Leading Ultrasound Portfolio Spanning the Continuum of Care Including Screening-a), Diagnosis, Treatment and Follow-up (GE HealthCare Radiology and Primary Care Cardiovascular Women's Health Point of Care & Handheld Industry-b) ~$3B ~$1B ~$1B ~$1B New Growth Areas Surgical Visualization & Guidance ~$1B Estimated Growth-c) ~4-6% ~3-5% ~3-5% ~8-10% ~10%+ Versana LOGIQ Vivid Voluson Vscan Air Venue bkActiv Product Portfolio Supported by Growing Demand for Digital Solutions and Service Capabilities Source: GE HealthCare Estimates (a Invenia ABUS or *Automated Breast Ultrasound (b - For the year 2021, Form 10 sub-segments and industry (c - For the period 2022-2025, Form 10 CAGR © 2022, General Electric Company. Proprietary information. All rights reserved. 51#52EGE HealthCare 1990s: 3D Fetal Ultrasound 2022: Real time 4D 25+ Years of Category Defining Innovation 66 I can do my diagnosis much faster, more detailed, and I get better images, a lot better images. Therefore, I can see anomalies or have the impression that I don't miss anything I might have missed some years ago. " - Prof. Tilman Esser 2022 2021 2022 Market-Defining Innovation 1990s 2003 2010 2018 Improve Outcomes - Clinical Innovation Enhancing Workflow Productivity - Al & Digital 3D Fetal Real Time 4D Ultrasound Handheld Ultrasound Al Optimization Wireless Whole- Body Scanning Pediatric 4D TEE Probe Ubiquitous Ultrasound - Miniaturization Innovation DNA & Customer Intimacy Will Continue to Drive Growth and Category Transformation © 2022, General Electric Company. Proprietary information. All rights reserved. 52 62#53Productivity Potential of Al in Ultrasound From: 1-2 minutes Voluson™ E10 g. Tls 0.2 E69766-18-09-07-1 GA-20w5d Tlb 0.2 MI 0.9 To: 10 seconds with the help of Al o Exam History available Voluson E10 AB P5 P3 Img P1 Calculating.. (GE HealthCare 09/07/2018 12:54:14 PM RM6C 73Hz/9.8cm 42°/0.9. Routine 2 Trim./OB HI M 7.70 -4.30- Gn 0 C7/M7- P4/E2 SRI II 3 SonoCNS Make sure the Transthalamic plane (TT) is visible in the A-plane area, adjust if needed. Then press Start Alignment P6 P4 V = 0.684 lit Vol.Angle Scan the QR code below with your mobile device to access the ISUOG Guidelines. ✓ Treely i P2 a 3D 3D Artificial Intelligence Implementation Enhancing Workflows and Expanding User Bases © 2022, General Electric Company. Proprietary information. All rights reserved. Θ 53#54Automation & AI - Opening Up New Markets bkActiv Vscan Air (GE HealthCare Voluson Expert 22 Empowering Smarter Surgery See More, Treat Faster Healthier Future for Women ~50K Neurosurgeons >235K General Surgeons >1.1M Primary Care Physicians >252M pregnancies per year Driving Enterprise Productivity While Improving Patient Outcomes © 2022, General Electric Company. Proprietary information. All rights reserved. 54#55Compounding Value Through Al & Digital Innovation (GE HealthCare • Care Team Collaboration Extends the care team with remote support Connects users in real-time 70 ..... Reporting & Workflow • Empowers clinicians by optimizing workflow • Provides comprehensive patient information Fleet Management • Enables control of fleets of devices and probes Powered by Edison TM Health Services A Single Platform to Enhance Every Ultrasound Exam © 2022, General Electric Company. Proprietary information. All rights reserved. 55#56Ultrasound Historical Financial Summary Revenue Key Drivers (GE HealthCare $3.2B $2.8B $2.7B ✓ Leading Position & Trusted Brand $2.3B $2.5B 2019A 2020A 2021A ! 2021 3Q YTD 2022 3Q YTD ✓ Global Distribution & Service Presence Segment EBIT Margin 27.9% 26.7% 25.3% 23.4% 23.7% Innovating Smart Devices & Digital Solutions ✓ Continuous Improvement to Optimize Value Stream 2019A 2020A 2021A ¡ 2021 3Q YTD 2022 3Q YTD © 2022, General Electric Company. Proprietary information. All rights reserved. 56#57Growth Strategies Driving Long-Term Success 29 T 24 8 3 4 1 V A 3 15 2 4 2 x 1 T B Kil R (GE HealthCare Grow Leadership Position Through Innovation & Commercial Intensity Expand into Attractive Adjacencies Broaden Digital Capabilities and Ecosystem in Ultrasound Revenue Expansion through Value Creation & Scale © 2022, General Electric Company. Proprietary information. All rights reserved. 40 57#58(GE HealthCare Patient Care Solutions Thomas Westrick Patient Care Solutions CEO#59Key Takeaways Decades of clinical innovation & trusted solutions Ubiquitous, clinically excellent, monitoring solutions portfolio Growing digital solutions with clinical decision support Mature markets, mid-single-digit growth, with high-growth adjacencies (GE HealthCare © 2022, General Electric Company. Proprietary information. All rights reserved. 59#60Patient Care Solutions at a Glance Clinical solutions providing real- $18B-a) Global End Markets time data, insights & support Estimated CAGR of 3-6%-b) 120 0.1 (a - Estimated for the year 2021 (b For the period 2022-2025 (c-For the year 2021 Industry-leading positions in Monitoring Solutions, Anesthesia, Diagnostic EKG & Maternal Infant Care Every 0.2 seconds anesthesia delivered on a GEHC solution $2,915M-c) Revenue 12.2%-c) Segment EBIT Margin 120 +fth Wt 120 60 prefactifustrifrifiada hechnafl 1121.20 (GE HealthCare 100M 80 patients monitored annually Large installed base 3 million devices © 2022, General Electric Company. Proprietary information. All rights reserved. 60 60#61Strong Portfolio to Address Patient Care Needs Monitoring Solutions Real-time critical care insights, visualization and decision support tools Anesthesia & Respiratory Care Diagnostic Cardiology Maternal Infant Care м (GE HealthCare Stabilize & Triage Surgical Care Critical Care Monitoring & Observation © 2022, General Electric Company. Proprietary information. All rights reserved. 61#62Solving for Today's Healthcare Challenges Estimated End Market Sizes-a) Numerous Macro Trends ... $18B end markets: 3-6% CAGR-b) Digital solutions growing +10% $18B $21B-C) 2021A 2025E (a - Including Digital Solutions of $2B and Service Capabilities of $4B (b - For the Period 2022 - 2025 (c - Represents the midpoint of the range (GE HealthCare Aging, clinically complex population Clinician shortages Inflationary pressure stressing healthcare viability + ඊ Connected and seamless data ... Leading To Multiple Unmet Needs Real-time visualization ... bedside or remote Workflow improvements with clinical decision support © 2022, General Electric Company. Proprietary information. All rights reserved. 62 62#63Innovating to Meet Customer Need Command Center Industry Firsts (GE HealthCare Innovation Pipeline Major NPI (Innovation) Near-Term Major NPI Launches Other Programs (Iterations) 2022 2023 2024 2025 Monitoring & Digital Solutions MUSE EKG Management Anesthesia & Respiratory Precision Monitoring Diagnostic Cardiology ALIVECORⓇ Accelerating Innovation Focused on Clinical Excellence and Workflow Solutions © 2022, General Electric Company. Proprietary information. All rights reserved. 63 63#64Improving Outcomes with Monitoring & Digital Solutions (GE HealthCare Monitoring Solutions Recently Launched Digital Applications Clinical Workflow Enhancements FlexAcuity Offerings Post-Acute Monitoring Data Platform Powered by Edison TM Health Services Digital Centralized Monitoring 197 Flexible monitoring to adapt with changing care needs Wearable, wireless continuous post-acute monitoring Real-time telemetry improving care collaboration and response time MURAL Real-time visualization and clinical decision support Device-Led, Clinical Data Acquisition → Insights → Insights at Scale © 2022, General Electric Company. Proprietary information. All rights reserved. 64 4#65Enhancing Health Systems Workflows Command Center ACUTE CARE Card-Med WWW373201 CHES A 3PMW-3125-01 a 3-3730-31 ED 23 EGE HealthCare Actionable Information Across Care Settings ✓ Capacity management ✓ Improved patient transitions ✓ Reduction of unnecessary transfers ✓ Reduction of length of stay Customer Value "What we were able to do in real-time, is understand where our beds will be later today and therefore, what patients we can accept now." - Dr. Sanjay Pattani AdventHealth, Central Florida Division Capture and Transform Data to Deliver Operational Workflow Improvements © 2022, General Electric Company. Proprietary information. All rights reserved. 69 65#66PCS Historical Financial Summary Revenue $3.7B $2.9B $2.7B $2.2B $2.1B 2019A 2020A 2021A 2021 Q3 YTD 2022 Q3 YTD Segment EBIT Margin 19.0% 12.2% 12.2% 9.7% 9.9% 2019A 2020A 2021A 2021 Q3 YTD 2022 Q3 YTD (GE HealthCare Key Drivers Increasing Innovation to Maintain and Advance Clinical Excellence Increasing the Use of Data at Scale to Advance Clinical & Operational Workflow Solutions ✓ Operational Improvements via Lean Supply chain . Lifecycle management Poised to Drive Growth in Near-Term © 2022, General Electric Company. Proprietary information. All rights reserved. 66 60#67Visible Path to EBIT Margin Expansion ~10-12%-a) Recent Historical Segment EBIT NPIs & Services Margin Range (a - Excludes 2020 due to COVID impact Note: Illustrative graph, not to scale Price & Commercial Execution EGE HealthCare High-teens VCP & Platforming Digital Medium-Term Target © 2022, General Electric Company. Proprietary information. All rights reserved. 20 67#68Our Growth Strategies to Drive Long-Term Success (GE HealthCare 24 29 4 1 V T A 3 15 2 4 2 x 1 T B Increase Innovation Across Portfolio Drive Digital Solutions that Improve Patient Outcomes and Productivity 强劲 Improve Margin Through Services & Consumables Growth Focus On Execution © 2022, General Electric Company. Proprietary information. All rights reserved. 68#69(GE HealthCare Pharmaceutical Diagnostics Kevin O'Neill Pharmaceutical Diagnostics CEO#70Key Takeaways Global leader in Precision Diagnostics with an industry-leading injectable pharmaceutical portfolio in contrast media and molecular imaging (GE HealthCare Driving innovation through funnel of new products and improving customer productivity Strong financial profile buoyed by recurring revenues and strong margins, built on a foundation of global commercial reach and a vertically integrated supply chain © 2022, General Electric Company. Proprietary information. All rights reserved. 70 70#71Pharmaceutical Diagnostics at a Glance Products used in over 100M-a) patient procedures Equivalent to 3 patient procedures every second Source: GE HealthCare Estimates (a For the year 2021 (b Estimated for the period 2022-2025 (c - Current Good Manufacturing Practices $2,018M-a) Revenue 34.3%-a) Segment EBIT Margin $10B-a) Global End Markets Industry CAGR of ~4-5%b) 7 CGMP-C) Manufacturing Sites (GE HealthCare O Only imaging provider that also manufactures diagnostic pharmaceuticals 8 Pre-clinical or clinical pipeline assets 20+ Brands © 2022, General Electric Company. Proprietary information. All rights reserved. 71#72Recurring Consumables Revenue, Mid-Single Digit Growth GE Health Care Estimated End Markets $10B end markets: 4-5% CAGR-a) $12B-b) $10B 2021A (a Estimated from 2022-2025 (b Represents the midpoint of the range 2025E Tailwinds Driving Demand In Attractive End Markets Demand for innovative therapies & precision diagnostics Growth in contrast media utilization gonn Aging populations and chronic disease prevalence Expanding patient access elevating number of procedures © 2022, General Electric Company. Proprietary information. All rights reserved. 72 12#73Pharmaceutical Diagnostics and What We Do Contrast Media-a) Molecular Imaging-b) (GE HealthCare Administered to Patient, Image Captured Amplified Diagnostic Images Enhanced Clinical Decisions (a X-ray, CT, MR, Interventional, and Ultrasound (b - Radioactive tracers used in SPECT and PET procedures Structural Imaging Focus Functional Imaging Focus Enabling Better Patient Outcomes © 2022, General Electric Company. Proprietary information. All rights reserved. الله 73#74Diagnostic Agent Portfolio with Industry-wide Compatibility ☑6 GE HealthCare Contrast Media Injectable agents used to improve visualization and diagnostic value of scans ~$5B Molecular Imaging Radioactive tracers used in SPECT & PET procedures ~$5B Why We Win in PDx 1 Continued innovation across established product portfolio and pipeline to improve clinical Industry-a) Estimated Growth-b) X-Ray/CT OMNIPAQUE™ (IOHEXOL) INJECTION Mid-Single Digit % MR Clariscan™ (gadoterate meglumine) injection for intravenous use VISIPAQUE™ OMNISCAN™ Mid-Single Digit % Ultrasound SPECT OPTISON™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) (IODIXANOL) INJECTION (GADODIAMIDE) INJECTION SONAZOID ulrichINJECT CT motion™ PERFLUOROBUTANE MICROBUBBLES TM DaTscan Ioflupane 1123 Injection (Neurology) MYOVIEW™ (Kit for the Preparation of Technetium Tc99m Tetrofosmin for Injection) (Cardiology) PET VIZAMYĽ Flutemetamol F18 Injection (Neurology) CERianna effectiveness and efficiency Scale advantages through 2 sophisticated vertically integrated supply chain in highly regulated industry (FLUOROESTRADIOL F 18 INJECTION (Oncology) 3 FASTlab Deep customer relationships and trust in brand built over many years TM Broad Capabilities with Increasing Focus on Attractive Growth Areas Source: GE HealthCare estimates Note: Not all products are available worldwide (a - For the year 2021; does not include Services or Digital markets (b For the Period 2022-2025 © 2022, General Electric Company. Proprietary information. All rights reserved. 74#75VOLUME Contrast Media: Grow Capacity and Innovate lodinated (X-Ray) Contrast Media Capacity Expansion ✓ Demand for iodinated contrast media to double over next decade-a) ✓ Expansion of existing API and fill-finish sites; Lean driving productivity ✓ Recent multi-year iodine supply agreement Investing to close the growing gap between supply and demand کھتے X-Ray (GE HealthCare Strategy to Drive Growth ✓ Capacity investment and pricing initiatives ✓ Improve efficiency and reduce waste Demand ✓ MRI ✓ Transform MRI industry with branded-generics Develop non-gadolinium alternative MRI agents ✓ Market Production Capacity Expand Optison in US and Sonazoid globally ✓ Increased use of contrast beyond diagnostics Today TIME In ten years Ultrasound Source: GE HealthCare estimates (a Illustrative graph, not to scale © 2022, General Electric Company. Proprietary information. All rights reserved. 75#76Molecular Imaging: Growth in Key Care Areas (GE HealthCare Leading position in Neurology Parkinson's prevalence is expected to double to ~14M by 2040 ✓ Leading player with DaTscan ✓ Pipeline aimed at improving workflow and image quality Building out Oncology platform Breast cancer represents 30% of female cancer ✓ Building out breast oncology platform ✓ Developing Immuno- oncology toolbox for Pharma with patient selection & therapy monitoring Innovating in Cardiology Coronary artery disease is the leading cause of death globally S ✓ Leading player with established Myoview & Rapiscan products ✓ Complementing our portfolio with Flurpiridaz, a pipeline PET-a) Track Record of Delivering Critical Solutions to Enable Life-Saving Disease Detection Source: National Library of Medicine; Parkinson disease: a public health approach. Technical Brief. Geneva: World Health Organization, 2022 (a Product for Coronary Artery Disease; Completed Phase III clinical trials © 2022, General Electric Company. Proprietary information. All rights reserved. 76#77Pharmaceutical Diagnostics: Pipeline CARE AREA PROGRAM Gd MR Radiology Non-Gd MR Dopamine transporter PET Neurology Dopamine transporter SPECT Cardiology Myocardial perfusion PET Estrogen receptor PET Oncology Her2 receptor PET Immuno-Diagnostics CD8 T-Cells PET (GE HealthCare PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKETING AUTHORIZATION Robust Pipeline of Products Focused on Key High-Growth Markets Note: GE Healthcare retains global rights to all pipeline assets reflected on this page © 2022, General Electric Company. Proprietary information. All rights reserved. 77#78Pharmaceutical Diagnostics Historical Financial Summary EGE HealthCare Revenue $2.0B $2.0B $1.8B $1.5B $1.5B 2019A 2020A 2021A I 2021 3Q YTD 2022 3Q YTD Segment EBIT Margin 36.5% 34.9% 34.3% 28.3% 27.7% Key Drivers Growing Procedural Demand Over Next Decade Rise of Molecular Imaging Strong Recurring Revenue and Margins Theranostics Creating Growth Opportunity 2019A 2020A 2021A I 2021 3Q YTD 2022 3Q YTD © 2022, General Electric Company. Proprietary information. All rights reserved. 78#79Our Growth Strategies to Drive Long-Term Success (GE HealthCare Expand Capacity to Meet Growing Demand 3 24 O 4 1 13 9 7 1 3 9 A " 4 구 E x 1 T 9 Commercial Execution Reflecting Product Value 1 Kil Increased R&D Investment in New Imaging Agents Capitalize on Attractive Growth Adjacencies © 2022, General Electric Company. Proprietary information. All rights reserved. 79#80(GE HealthCare Commercial Strategy & Execution Catherine Estrampes U.S. & Canada CEO#81Key Takeaways (GE HealthCare Trusted partner: strong customer relationships, providing a platform for sustainable growth Unique customer value proposition: innovative products, technologies, services and solutions Regional scale: rely on global capabilities to solve complex problems for our customers locally © 2022, General Electric Company. Proprietary information. All rights reserved. 81#82Trusted Partner With Strong Global Presence (GE HealthCare 2021 GE Health Care Revenue US & Canada $7.4 billion R&D Presence Manufacturing Site Customer Service EMEA $4.5 billion China region . $2.7 billion Intercontinental $3.0 billion 4M+ Installed Base >10,000 Global Sales Force 1,500 Channel Partners 8,500 Field Engineers 1,800 Clinical Application & R&D Specialists Focused Operating Model With Four Regional Leaders To Take Advantage of Scale Where It Matters Most © 2022, General Electric Company. Proprietary information. All rights reserved. 82#83Unique Value Proposition to Customers Deep customer relationships · ✈ Tailored regional execution Technology leader Solutions partner Rely on GEHC for mission-critical capabilities • Multi-channel commercial model • Long-standing delivery of industry-defining innovations • Full suite of digital, Al and services platform (GE HealthCare × Best-in-class service • Global scale and dedicated team of highly-trained service engineers Well-Positioned To Attract New Customers, Increase Customer Retention And Long-Term Value © 2022, General Electric Company. Proprietary information. All rights reserved. 83#84Regional Teams Deliver Solutions at Scale to Customers. Customer Needs Addressing labor challenges (GE HealthCare GE HealthCare Customer Team Care Pathway Specialists Product Sales Specialists ☑ Improving patient throughput Navigating capital decisions and cyber risks Delivering better patient outcomes Digital and Data Science Specialists Customer Clinical Scientists Regional ② Cost controls through innovative monitoring Managers Account Managers Meeting Customer Needs At Scale While Improving Outcomes At Lower Costs Clinical Application Specialists Service Engineers © 2022, General Electric Company. Proprietary information. All rights reserved. 84 =#85Innovating with HCA to Improve Clinical Experience Care HCA Healthcare (GE HealthCare 35M Annual Patient Encounters 2,500 Sites of Care BRF (GE HealthCare DIGITAL & CLINICAL TRANSFORMATION CLINICAL EXPERIENCE MODERNIZING WORKFLOW I 25-year Partnership Supports Commitment to Care and Improvement of Human Life © 2022, General Electric Company. Proprietary information. All rights reserved. I 85 86#86GE GE HealthCare Q&A#87(GE HealthCare Financial Strategy Helmut Zodl CFO#88Our Financial Strategy 2 Delivering Sustainable, High- Quality Performance Optimizing Business 3 Through Lean GEGE HealthCare Revolution Accelerating 1 Innovation & Driving Growth S ✓ Driving Growth Mid-single Digit Organic Revenue Growth* High-teens to 20% Adj. EBIT Margin* Strong Free Cash Flow* Generation Disciplined Capital Allocation Aligning Capital Allocation 4 to Strategy *Non-GAAP Financial Measure. Medium-term targets. Significant Shareholder Value Creation Opportunity © 2022, General Electric Company. Proprietary information. All rights reserved. 88 88#89Accelerating Innovation & Driving Growth 3% Revenue Growth 2019A-2021A CAGR Accelerating Innovation & Driving Growth Growth Drivers lil Customer Demand and Industry Growth MSD% Medium-term Target New Product Introductions and Digital Solutions Enhanced Commercial Execution + Increased R&D Spending Note: Illustrative graph, not to scale * Non-GAAP Financial Measure (a- on an organic basis Leadership Positions Across Markets Drive Growth © 2022, General Electric Company. Proprietary information. All rights reserved. 89#90Investing in R&D to Drive Growth and Margin Accelerating Innovation & Driving Growth $1B + 2022E R&D Key Actions Increase Pace of NPIs at Higher Gross Margins Expand Digital / Al Capabilities 35%+ NPI vitality-a) Optimize Product Platforms. Portfolio / R&D Prioritization Process Allocating R&D to High ROI Projects (a-Defined as percentage of product orders received in 2021 in Imaging, Ultrasound and PCS segments for products introduced in the last 12 months. © 2022, General Electric Company. Proprietary information. All rights reserved. 80 90#91Commercial Execution Delivering Mid-Single Digit Growth Q3 YTD Organic Revenue Growth* of 6% Market Position Accelerating Innovation & Driving Growth Revenues by Segment Organic Revenue Growth* Largest Global Installed Base $13.0B $13.4B $1.5B $1.5B 2% Care Across the Patient Journey $2.2B $2.1B (0%) $2.3B $2.5B 6% Global Brand Recognition 8% $7.0B $7.3B 2021 Q3 YTD 2022 Q3 YTD ■Imaging Ultrasound PCS PDX Commercial Infrastructure and Supply Chain Optimization Delivering More Value for Customers Through Increased Focus on Commercial Excellence Note: Illustrative graph, not to scale * Non-GAAP Financial Measure © 2022, General Electric Company. Proprietary information. All rights reserved. 91#92Delivering Sustainable, High-Quality Performance Recurring Revenue-a) ~50% Key Drivers Lifecycle Services Pharmaceutical Diagnostics Delivering Sustainable, High-Quality Performance Digital Solutions and Software ++ Consumables and Value-Added Offerings. ■ Recurring ■ Non-Recurring Significant Recurring Revenue Driven by Our Industry-Leading Services and PDx Businesses (a - For the year 2021 © 2022, General Electric Company. Proprietary information. All rights reserved. 92 92#93Optimizing Business Through Lean % of revenue Adjusted EBIT Margin* High-teens to 20% 15% - 18% Historic 2019A2021A Note: Illustrative graph, not to scale * Non-GAAP Financial Measure Medium-term Target Optimizing Business Through Lean Implementing Lean to Drive Margins & FCF* Sales and Marketing Effectiveness M Price and Value Variable Cost Productivity M Simplifying Operating Model / G&A Reinvesting Operational Savings to Driving Top- and Bottom-line Growth © 2022, General Electric Company. Proprietary information. All rights reserved. 93#94Implementing Lean Across our Business Margin Expansion • Price Improvement vs. Inflation Portfolio Optimization • Optimizing Business Through Lean SKU Rationalization and Configuration Management Optimizing CapEx / G&A • Real Estate Footprint Inventory Turns • Implement Pull Systems to Reduce Lead Times ១ Using Lean to Sustainably Improve Our Business Every Day © 2022, General Electric Company. Proprietary information. All rights reserved. 94#95Lean Implementation Driving Margin Expansion -15% 2022E Adj. EBIT Margin -a)* Adj. EBIT Margin* High-teens to 20% Spin Dis- synergies Volume & Lean Optimization Medium Term Target Adj. EBIT Margin* Lean Margin Drivers Commercial Excellence Optimizing Business Through Lean KI Higher Margin Products from Innovation RO Portfolio & Supply Chain Optimization Cost and Expense Productivity Headwinds Exerting Pressure on Near-term EBIT but Long-term Trajectory Remains Intact Note: Illustrative graph, not to scale * Non-GAAP Financial Measure (a - 2022E GEHC figures consistent with GE Company guide for HealthCare segment of MSD organic revenue growth and operating profit of $2.6B+ © 2022, General Electric Company. Proprietary information. All rights reserved. 95 95#96Solid Cash Flow Generation and Financial Flexibility Free Cash Flow Conversion*-a) 85%+ Medium-term Target Free Cash Flow Conversion* Optimizing Business Through Lean Free Cash Flow* Expected to Grow with Future Earnings Commitment to Strong Investment Grade Ratings Maintain Strong Balance Sheet with Flexibility Strong Liquidity on Day 1 with $1.8B of Cash and $3.5B Credit Facility Availability Robust Cash Generation Directed Towards Near-Term Debt Repayment and Investment in Organic & Inorganic Growth * Non-GAAP Financial Measure (a - FCF conversion* = FCF* / Adjusted Net Income* © 2022, General Electric Company. Proprietary information. All rights reserved. 96#97Aligning Capital Allocation to Strategy Investing in Organic Revenue Growth M&A ✓ Increasing R&D and Capex ✓ Focus on Differentiation and Digital / AI Disciplined Investments ✓ Adjacent Opportunities, e.g. BK Medical $2.5B Cumulative R&D investment from 2019-2021 4 Acquisitions announced since 2020 Aligning Capital Allocation to Strategy Minority Investments & Strategic Collaborations ✓ Augmented Product Pipeline ✓ Early Engagement with Companies for Potential M&A 20+ Investments / collaborations since 2020 Commitment to Maintain Strong Investment Grade Rating with Robust and Consistent Cash Flow © 2022, General Electric Company. Proprietary information. All rights reserved. 97#98Outlook Organic Revenue Growth* 2022E-a) MSD • Adjusted EBIT* $2.7B+ (equal to $2.6B+ on GE basis) FCF* $1.8 - 2.0B (equal to $2.1 to $2.3B on GE basis) (GE HealthCare • Continued order book growth Greater components access and increased fulfillment • Proactive cost and price actions • Volume growth and productivity • Inventory build for ramp in demand Focused working capital improvements On Track to Finish 2022 with Solid Performance * Non-GAAP Financial Measure 98 © 2022, General Electric Company. Proprietary information. All rights reserved. (a- 2022E GEHC figures consistent with GE Company guide for HealthCare segment of MSD organic revenue growth, operating profit of $2.6B+ and FCF of $2.1-2.3B (after the impact of carve-out adjustments, primarily due to taxes)#99Long-Term Value Creation Framework (GE HealthCare Driving Growth MSD Organic Revenue Growth* + Adj EBIT Margin Expansion High-teens to 20%* Strong FCF* Generation Disciplined Capital Allocation Strong financial position Investment in Organic growth Investment in M&A Shareholder Value Creation *Non-GAAP Financial Measure. Medium-term targets. © 2022, General Electric Company. Proprietary information. All rights reserved. 99 9#100GE GE HealthCare Q&A#101(GE HealthCare Closing Remarks Peter Arduini CEO#102Significant Value Creation Opportunity Visibility to Growth Solid demand and backlog Continued R&D investment Commercial execution focus (GE HealthCare Expanding Adjusted EBIT Margin* Strategic pricing Higher-margin products Product line simplification % Revenue Growth 3% 2019A 2021A CAGR MSD % *-a) Medium-term Target % Adj. EBIT Margin* 15% - 18% High-teens to 20% Historic 2019A 2021A Medium-term Target Note: Illustrative graph, not to scale * Non-GAAP Financial Measure (a- on an organic basis Growth and Margin Expansion Driving Strong Shareholder Value © 2022, General Electric Company. Proprietary information. All rights reserved. 102#103Driving the Future of Healthcare * Non-GAAP Financial Measure (GE HealthCare Global leader in precision care • Unparalleled brand, scale, customer relationships and capabilities Outstanding portfolio of innovative products and solutions • Breaking new ground across care pathways, devices and digital solutions Driving growth and margin expansion • Clear path to MSD organic revenue growth* and high-teens to 20% margins* Creating Long-term Value as a Faster-growing, More Profitable Company © 2022, General Electric Company. Proprietary information. All rights reserved. 103#104Thank You Upcoming Events: J.P. Morgan Annual Healthcare Conference 4Q'22 Earnings Call January 10, 2023 January 30, 2023#105DISCLAIMER: The statements in today's videos by the following individuals are based on their own opinions and on results that were achieved in their unique settings. Because there is no "typical" hospital and many variables exist, i.e., hospital size, case mix, etc. there can be no guarantee that other customers will achieve the same results. Hollis Potter, M.D. Tom Schrack Sonali Basu, M.D. Alfred Abuhamad Dr. Ken Herrmann Mike Schlosser, M.D. GE HealthCare Command Center customer representatives Dr. Basu is a paid consultant for GEHC and was compensated for participation in today's testimonial video. The statements by Dr. Basu are based on her own opinions and on results that were achieved in her unique setting. Because there is no "typical" hospital and many variables exist, i.e., size, case mix, etc. there can be no guarantee that other customers will achieve the same hospital results.#106GE GE HealthCare GE HealthCare Investor Day | December 8, 2022#107Supplemental Materials#108Non-GAAP Financial Measures EGE HealthCare The non-GAAP financial measures disclosed in this presentation are supplemental measures of our performance and our liquidity that we believe help investors understand our financial condition, cash flows and operating results and assess our future prospects. We believe that presenting these non-GAAP financial measures, in addition to the corresponding U.S. GAAP financial measures, are important supplemental measures that exclude non-cash or other items that may not be indicative of or are unrelated to our core operating results and the overall health of our company. We believe that these non-GAAP financial measures provide investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes of management." We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance. When read in conjunction with our U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in our underlying businesses and can be used by management as one basis for financial, operational, and planning decisions. Finally, these measures are often used by analysts and other interested parties to evaluate companies in our industry. Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes, thereby affecting their comparability from company to company. In order to compensate for these and the other limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. Readers should review the reconciliations and should not rely on any single financial measure to evaluate our business. We define these non-GAAP financial measures as: Organic revenue: Total revenues excluding the effects of: (1) net sales from recent acquisitions and divestitures with less than a full year of comparable net sales; and (2) foreign currency exchange rate fluctuations in order to present revenue on a constant currency basis. Adjusted EBIT: Net income attributable to GE HealthCare excluding the effects of: (1) Interest and other financial charges - net; (2) Non-operating benefit costs; (3) Provision for income taxes; (4) Income (loss) from discontinued operations, net of taxes; (5) Net income (loss) attributable to noncontrolling interests; (6) restructuring costs; (7) acquisition, disposition related charges; (8) Spin-Off and separation costs; (9) (gain)/loss of business dispositions/divestments; (10) amortization of acquisition-related intangible assets; and (11) investment revaluation (gain)/loss. In addition, we may from time to time consider excluding other nonrecurring items to enhance comparability between periods. Adjusted EBIT margin: Non-GAAP financial measure of Adjusted EBIT divided by the U.S. GAAP financial measure Total revenues for the same period. We believe Adjusted EBIT and Adjusted EBIT margin provide management and investors with additional understanding of our business by highlighting the results from ongoing operations and the underlying profitability factors. These metrics exclude interest expense, interest income, and tax expense, as well as unique and/or non-cash items, that can have a material impact on our results. We believe this provides additional insight into how our businesses are performing, on a normalized basis. However, Adjusted EBIT and Adjusted EBIT margin should not be construed as inferring that our future results will be unaffected by the items for which the measure adjusts. Adjusted Net Income: Net income attributable to GE HealthCare excluding (1) Non-operating benefit costs; (2) restructuring costs; (3) acquisition and disposition related charges (benefits); (4) Spin-Off and separation costs; (5) (gain)/loss of business dispositions/divestments; (6) amortization of acquisition-related intangible assets; (7) investment revaluation (gain)/loss; (8) tax effect of reconciling items (items 1-7); (9) impact of tax law changes and (10) Income (loss) from discontinued operations, net of taxes. In addition, we may from time to time consider excluding other nonrecurring items to enhance comparability between periods. We believe Adjusted net income provides investors with improved comparability of underlying operating results and a further understanding and additional transparency regarding how we evaluate our business. Adjusted net income also provides management and investors with additional perspective regarding the impact of certain significant items on our combined earnings. However, Adjusted net income should not be construed as inferring that our future results will be unaffected by the items for which the measure adjusts. Free cash flow: Cash from (used for) operating activities - continuing operations adjusting for the effects of (1) additions to PP&E and internal-use software; (2) dispositions of PP&E; and (3) impact of factoring programs. We believe that Free cash flow provides management and investors with an important measure of our ability to generate cash on a normalized basis. Free cash flow also provides insight into our flexibility to allocate capital, including reinvesting in the company for future growth, paying down debt, paying dividends, and pursuing other opportunities that may enhance stockholder value. We believe investors may find it useful to compare Free cash flow performance without the effects of the factoring program discontinuation. The cash flow from operating activity ("CFOA") impact from factoring programs discontinued in 2021 represents the cash that we would have otherwise collected in the period had customer receivables not been previously sold to GE in those discontinued programs. We typically invest in PP&E over multiple periods to support new product introductions and increases in manufacturing capacity and to perform ongoing maintenance of our manufacturing and distribution operations. We believe that while PP&E expenditures and dispositions will fluctuate period to period, we will need to maintain a material level of net PP&E spend to maintain ongoing operations and growth of the business. Our historical Free cash flow includes interest expense associated with the internal and external factoring of current receivables and other financial charges. Interest expense associated with external debt that is currently held by GE is not currently included in the combined financial statements and related notes. Additionally, Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact the measures do not deduct the payments required for debt repayments. © 2022, General Electric Company. Proprietary information. All rights reserved. 108#109GEHC Organic Revenue Reconciliation GE HealthCare ($ in Millions) Total revenues 2019 2020 % change 2020 2021 % change 9M '21 9M '22 % change 3Q '21 3Q '22 % change $16,633 $17,164 3% $17,164 $17,585 2% $12,996 Less: Acquisitions-a) -- 36 19 $13,403 175 3% $4,305 $4,576 6% 61 Less: Dispositions-b) 76 21 81 Less: Foreign currency exchange Organic revenue* $16,557 (36) $17,143 308 4% $17,083 $17,258 1% $12,996 (484) $13,711 (232) 6% $4,305 $4,747 10% (a Represents revenue attributable to acquisitions from the date we completed the transaction through the end of four quarters following the transaction. (b - Represents revenue attributable to dispositions for the four quarters preceding the disposition date. © 2022, General Electric Company. Proprietary information. All rights reserved. 109#110Segment Organic Revenue Reconciliation Imaging ($ in Millions) Total revenues 2019 2020 $9,096 $8,959 (GE HealthCare % change 2020 2021 % change 9M '21 9M '22 % change (2%) $8,959 $9,433 5% $6,996 $7,276 4% 3Q '21 $2,351 3Q '22 $2,516 % change 7% Less: Acquisitions-a) Less: Dispositions-b) Less: Foreign currency exchange -- (24) 163 (255) (125) Organic revenue* $9,096 $8,983 (1%) $8,959 $9,270 3% $6,996 $7,530 8% $2,351 $2,640 12% Ultrasound ($ in Millions) 2019 2020 % change 2020 2021 % change 9M $21 9M '22 % change 3Q '21 3Q '22 % change Total revenues $2,783 $2,703 (3%) $2,703 $3,172 17% $2,274 $2,466 8% $735 $823 12% Less: Acquisitions-a) 174 61 Less: Dispositions-b) Less: Foreign currency exchange Organic revenue* PCS ($ in Millions) Total revenues Less: Acquisitions-a) Less: Dispositions-b) $2,783 (4) $2,707 56 (116) -- (56) (3%) $2,703 $3,116 15% $2,274 $2,408 6% $735 $818 11% 2019 2020 % change 2020 2021 % change 9M '21 9M '22 % change 3Q '21 3Q '22 % change $2,723 $3,675 35% $3,675 $2,915 (21%) $2,180 $2,130 (2%) $708 $701 (1%) Less: Foreign currency exchange 1 1 32 (48) (22) Organic revenue* PDx ($ in Millions) $2,723 $3,674 35% $3,674 $2,883 (22%) $2,180 $2,178 (0%) $708 $723 2% 2019 2020 % change 2020 2021 % change 9M '21 9M '22 % change 3Q '21 Total revenues $1,993 $1,780 (11%) $1,780 $2,018 13% $1,518 $1,485 (2%) $504 3Q '22 $522 % change 4% Less: Acquisitions-a) 36 19 2 Less: Dispositions-b) 76 21 81 Less: Foreign currency exchange Organic revenue* $1,917 (10) $1,733 53 (10%) $1,699 $1,946 15% $1,518 (64) $1,547 2% $504 (29) $552 10% (a - Represents revenue attributable to acquisitions from the date we completed the transaction through the end of four quarters following the transaction. (b - Represents revenue attributable to dispositions for the four quarters preceding the disposition date. © 2022, General Electric Company. Proprietary information. All rights reserved. * Non-GAAP financial measure. 110#111Adj. EBIT Reconciliation ($ in Millions) Net income attributable to GE Health Care Add: Interest and other financial charges - net Add: Non-operating benefit costs Less: Provision for income taxes Less: Income (loss) from discontinued operations, net of taxes Add: Net income attributable to noncontrolling interests EBIT (Non-GAAP) Add: Restructuring costs-a) Add: Acquisition and disposition related charges (benefits)-b) Add: Spin-Off and separation costs-c) Add: (Gain)/loss of business dispositions / divestments-d) Add: amortization of acquisition related intangible assets Add: investment revaluation (gain)/loss-e) Adjusted EBIT (Non-GAAP) Net income margin (US GAAP) Adjusted EBIT Margin (Non-GAAP) 2019 2020 2021 $1,524 $13,846 $2,247 88 66 40 9 5 3 (410) (652) (600) (128) 11,839 18 29 51 46 $2,188 $2,781 $2,918 160 134 155 -- 2 14 54 (3) 3 (2) 92 83 90 1 (22) (3) $2,492 $2,981 $3,172 9.2% 80.7% 12.8% 15.0% 17.4% 18.0% (GE HealthCare (a Consists of severance, facility closures, and other charges associated with historical restructuring programs. (b - Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. (c Costs incurred in the Spin-Off and separation from GE as well as the planned IPO of GE's Healthcare business in 2019 including system implementation, audit and advisory fees, legal entity separation, and other one-time costs. (d Consists of gains and losses resulting from the sale of assets and investments. (e - Primarily relates to valuation adjustments for equity investments. © 2022, General Electric Company. Proprietary information. All rights reserved. 111#112Adj. Net Income Reconciliation ($ in Millions) Net income attributable to GE Health Care Add: Non-operating benefit (income) costs Add: Restructuring costs-a) Add: Acquisition and disposition related charges (benefits) -b) Add: Spin-Off and separation costs-c) Add: (Gain)/loss of business dispositions/divestments-d) Add: Amortization of acquisition-related intangible assets Add: Investment revaluation (gain)/loss-e) Add: Tax effect of reconciling items Less: Impact of tax law changes-f) 2019 2020 2021 $1,524 $13,846 $2,247 སྐྱེ - 8 @ ྣ · མྱེ 。 5 3 160 134 155 14 2 3 (2) 83 90 (22) (3) (73) (51) (62) 40 77 Less: Income (loss) from discontinued operations, net of taxes Adjusted Net Income (Non-GAAP) (128) $1,892 11,839 18 $2,121 $2,347 (GE HealthCare (a Consists of severance, facility closures, and other charges associated with historical restructuring programs (b - Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions (c Costs incurred in the Spin-Off and separation from GE as well as the planned IPO of GE's Healthcare business in 2019 including system implementation, audit and advisory fees, legal entity separation, and other one-time costs (d- Consists of gains and losses resulting from the sale of assets and investments (e-Primarily relates to valuation adjustments for equity investments (f Consists of benefit from U.K. tax rate change © 2022, General Electric Company. Proprietary information. All rights reserved. 112#113Free Cash Flow Reconciliation ($ in Millions) Cash from operating activities - continuing operations Add: Additions to PP&E and internal-use software Add: Dispositions of PP&E Add: Impact of factoring programs-a) Free cash flow* (GE HealthCare 2019 2020 2021 $1,838 $2,618 $1,607 (331) (259) (248) 52 16 15 341 88 1,453 $1,900 $2,463 $2,827 (a Adjustment to present net cash flows from operating activities from continuing operations had we not factored receivables with WCS. By the end of 2021, factoring of receivables with WCS was discontinued * Non-GAAP financial measure © 2022, General Electric Company. Proprietary information. All rights reserved. 113#114Empty#115Definitions (Cont'd) IGT IDN MICT ML MR MRI MSD Image Guided Therapy Integrated Delivery Network Molecular Imaging and Computed Tomography Machine Learning Magnetic Resonance Magnetic Resonance Imaging Mid-Single Digit Nuclear Medicine NM NPls New Product Introductions NVBP OR PCS PCCT National Volume Based Procurement Operating Room Patient Care Solutions Photon-Counting Computed Tomography (GE HealthCare © 2022, General Electric Company. Proprietary information. All rights reserved. 115#116Definitions (Cont'd) PDx Pharmaceutical Diagnostics (GE HealthCare PET Products Recurring Revenues RPM RSNA Services SPECT TAM Positron Emission Tomography Sales of medical equipment, contrast agents (PDX), software licenses (excludes hosting/SaaS), Options & Upgrades Maintenance & repair services for equipment, contrast agents (PDX), Enterprise Digital Solutions (EDS), and other consumables Remote Patient Monitoring Radiological Society of North America Maintenance & repair services for equipment, training, parts, software hosting (Software as a Service (SaaS)) Single-photon Emission Computerized Tomography Total Addressable Market VCP Variable Cost Productivity YOY Year Over Year YTD Year To Date © 2022, General Electric Company. Proprietary information. All rights reserved. 116